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S ince the 2001 update of the American Heart Association(AHA)/American College of Cardiology (ACC) consen-
sus statement on secondary prevention (1), important evi-
dence from clinical trials has emerged that further supports
and broadens the merits of aggressive risk-reduction therapies
for patients with established coronary and other atheroscle-
rotic vascular disease, including peripheral arterial disease,
atherosclerotic aortic disease, and carotid artery disease. This
growing body of evidence confirms that aggressive compre-
hensive risk factor management improves survival, reduces
recurrent events and the need for interventional procedures,
and improves quality of life for these patients.
Compelling evidence from recent clinical trials and revised
practice guidelines provided the impetus for this update of the
2001 recommendations with evidence-based results (Table
1). Classification of Recommendations and Level of Evi-
dence are expressed in ACC/AHA format, as detailed in
Tables 2 and 3. Recommendations made herein are based
largely on major practice guidelines from the National Insti-
tutes of Health and ACC/AHA. In many cases, these practice
guidelines were supplemented by research findings published
after the publication of the primary reference(s). Thus, the
development of the present statement involved a process of
partial adaptation of other guideline statements and reports
and supplemental literature searches (2–32). (For specific
search criteria, see the Appendix.) The findings from addi-
tional lipid reduction trials (33–37) involving more than
50 000 patients resulted in new optional therapeutic targets,
which were outlined in the 2004 update of the National Heart,
Lung, and Blood Institute’s Adult Treatment Panel (ATP) III
report (6). These changes defined optional lower target
cholesterol levels for very high-risk coronary heart disease
(CHD) patients, especially those with acute coronary syn-
dromes, and expanded indications for drug treatment. Subse-
quent to the 2004 update of ATP III, 2 additional trials (8,9)
demonstrated cardiovascular benefit for lipid lowering signif-
icantly below current cholesterol goal levels for those with
chronic CHD. These new trials allow for alterations in
guidelines, such that low-density lipoprotein cholesterol
(LDL-C) should be 100 mg/dL for all patients with CHD
and other clinical forms of atherosclerotic disease, but in
addition, it is reasonable to treat to LDL-C 70 mg/dL in
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TABLE 1. AHA/ACC Secondary Prevention for Patients With Coronary and Other Vascular Disease*: 2006 Update
Intervention Recommendations With Class of Recommendation and Level of Evidence
SMOKING:
Goal
Complete cessation. No exposure to
environmental tobacco smoke.
• Ask about tobacco use status at every visit. I (B)
• Advise every tobacco user to quit. I (B)
• Assess the tobacco user’s willingness to quit. I (B)
• Assist by counseling and developing a plan for quitting. I (B)
• Arrange follow-up, referral to special programs, or pharmacotherapy (including nicotine replacement and
bupropion). I (B)
• Urge avoidance of exposure to environmental tobacco smoke at work and home. I (B)
BLOOD PRESSURE CONTROL:
Goal
140/90 mm Hg
or
130/80 mm Hg if patient has diabetes
or chronic kidney disease
For all patients:
• Initiate or maintain lifestyle modification—weight control; increased physical activity; alcohol moderation;
sodium reduction; and emphasis on increased consumption of fresh fruits, vegetables, and low-fat dairy
products. I (B)
For patients with blood pressure >140/90 mm Hg (or >130/80 mm Hg for individuals with chronic
kidney disease or diabetes):
• As tolerated, add blood pressure medication, treating initially with -blockers and/or ACE inhibitors, with
addition of other drugs such as thiazides as needed to achieve goal blood pressure. I (A)
[For compelling indications for individual drug classes in specific vascular diseases, see Seventh Report of the Joint
National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7).]4
LIPID MANAGEMENT:
Goal
LDL-C 100 mg/dL
If triglycerides are 200 mg/dL,
non-HDL-C should be 130 mg/dL†
For all patients:
• Start dietary therapy. Reduce intake of saturated fats (to 7% of total calories), trans-fatty acids, and
cholesterol (to 200 mg/d). I (B)
• Adding plant stanol/sterols (2 g/d) and viscous fiber (10 g/d) will further lower LDL-C.
• Promote daily physical activity and weight management. I (B)
• Encourage increased consumption of omega-3 fatty acids in the form of fish‡ or in capsule form (1 g/d)
for risk reduction. For treatment of elevated triglycerides, higher doses are usually necessary for risk
reduction. IIb (B)
For lipid management:
Assess fasting lipid profile in all patients, and within 24 hours of hospitalization for those with an acute
cardiovascular or coronary event. For hospitalized patients, initiate lipid-lowering medication as recommended
below before discharge according to the following schedule:
• LDL-C should be 100 mg/dL I (A), and
• Further reduction of LDL-C to 70 mg/dL is reasonable. IIa (A)
• If baseline LDL-C is 100 mg/dL, initiate LDL-lowering drug therapy.§ I (A)
• If on-treatment LDL-C is 100 mg/dL, intensify LDL-lowering drug therapy (may require LDL-lowering
drug combination). I (A)
• If baseline LDL-C is 70 to 100 mg/dL, it is reasonable to treat to LDL-C 70 mg/dL. IIa (B)
• If triglycerides are 200 to 499 mg/dL, non-HDL-C should be 130 mg/dL. I (B), and
• Further reduction of non-HDL-C to 100 mg/dL is reasonable. IIa (B)
• Therapeutic options to reduce non-HDL-C are:
f More intense LDL-C–lowering therapy I (B), or
f Niacin¶ (after LDL-C–lowering therapy) IIa (B), or
f Fibrate therapy# (after LDL-C–lowering therapy) IIa (B)
• If triglycerides are 500 mg/dL#, therapeutic options to prevent pancreatitis are fibrate¶ or niacin¶
before LDL-lowering therapy; and treat LDL-C to goal after triglyceride-lowering therapy. Achieve
non-HDL-C 130 mg/dL if possible. I (C)
PHYSICAL ACTIVITY:
Goal
30 minutes, 7 days per week (minimum
5 days per week)
• For all patients, assess risk with a physical activity history and/or an exercise test, to guide prescription. I (B)
• For all patients, encourage 30 to 60 minutes of moderate-intensity aerobic activity, such as brisk walking, on
most, preferably all, days of the week, supplemented by an increase in daily lifestyle activities (eg, walking
breaks at work, gardening, household work). I (B)
• Encourage resistance training 2 days per week. IIb (C)
• Advise medically supervised programs for high-risk patients (eg, recent acute coronary syndrome or
revascularization, heart failure). I (B)
WEIGHT MANAGEMENT:
Goal
Body mass index: 18.5 to 24.9 kg/m2
Waist circumference: men 40 inches,
women 35 inches
• Assess body mass index and/or waist circumference on each visit and consistently encourage weight
maintenance/reduction through an appropriate balance of physical activity, caloric intake, and formal
behavioral programs when indicated to maintain/achieve a body mass index between 18.5 and 24.9
kg/m2. I (B)
• If waist circumference (measured horizontally at the iliac crest) is 35 inches in women and 40
inches in men, initiate lifestyle changes and consider treatment strategies for metabolic syndrome as
indicated. I (B)
• The initial goal of weight loss therapy should be to reduce body weight by approximately 10% from baseline.
With success, further weight loss can be attempted if indicated through further assessment. I (B)
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such patients. When the 70-mg/dL target is chosen, it may
be prudent to increase statin therapy in a graded fashion to
determine a patient’s response and tolerance. Furthermore, if
it is not possible to attain LDL-C 70 mg/dL because of a
high baseline LDL-C, it generally is possible to achieve
LDL-C reductions of 50% with either statins or LDL-C–
lowering drug combinations. Moreover, this guideline for
patients with atherosclerotic disease does not modify the
recommendations of the 2004 ATP III update for patients
without atherosclerotic disease who have diabetes or multiple
TABLE 1. Continued
Intervention Recommendations With Class of Recommendation and Level of Evidence
DIABETES MANAGEMENT:
Goal
HbA1c 7%
• Initiate lifestyle and pharmacotherapy to achieve near-normal HbA1c. I (B)
• Begin vigorous modification of other risk factors (eg, physical activity, weight management, blood
pressure control, and cholesterol management as recommended above). I (B)
• Coordinate diabetic care with patient’s primary care physician or endocrinologist. I (C)
ANTIPLATELET AGENTS/
ANTICOAGULANTS:
• Start aspirin 75 to 162 mg/d and continue indefinitely in all patients unless contraindicated. I (A)
f For patients undergoing coronary artery bypass grafting, aspirin should be started within 48 hours
after surgery to reduce saphenous vein graft closure. Dosing regimens ranging from 100 to 325
mg/d appear to be efficacious. Doses higher than 162 mg/d can be continued for up to 1 year. I (B)
• Start and continue clopidogrel 75 mg/d in combination with aspirin for up to 12 months in patients after acute
coronary syndrome or percutaneous coronary intervention with stent placement (1 month for bare metal
stent, 3 months for sirolimus-eluting stent, and 6 months for paclitaxel-eluting stent). I (B)
f Patients who have undergone percutaneous coronary intervention with stent placement should initially
receive higher-dose aspirin at 325 mg/d for 1 month for bare metal stent, 3 months for sirolimus-eluting
stent, and 6 months for paclitaxel-eluting stent. I (B)
• Manage warfarin to international normalized ratio2.0 to 3.0 for paroxysmal or chronic atrial fibrillation or
flutter, and in post–myocardial infarction patients when clinically indicated (eg, atrial fibrillation, left ventricular
thrombus). I (A)
• Use of warfarin in conjunction with aspirin and/or clopidogrel is associated with increased risk of bleeding and
should be monitored closely. I (B)
RENIN-ANGIOTENSIN-
ALDOSTERONE SYSTEM
BLOCKERS:
ACE inhibitors:
• Start and continue indefinitely in all patients with left ventricular ejection fraction 40% and in those
with hypertension, diabetes, or chronic kidney disease, unless contraindicated. I (A)
• Consider for all other patients. I (B)
• Among lower-risk patients with normal left ventricular ejection fraction in whom cardiovascular risk
factors are well controlled and revascularization has been performed, use of ACE inhibitors may be
considered optional. IIa (B)
Angiotensin receptor blockers:
• Use in patients who are intolerant of ACE inhibitors and have heart failure or have had a myocardial
infarction with left ventricular ejection fraction 40%. I (A)
• Consider in other patients who are ACE inhibitor intolerant. I (B)
• Consider use in combination with ACE inhibitors in systolic-dysfunction heart failure. IIb (B)
Aldosterone blockade:
• Use in post–myocardial infarction patients, without significant renal dysfunction** or hyperkalemia††,
who are already receiving therapeutic doses of an ACE inhibitor and -blocker, have a left ventricular
ejection fraction 40%, and have either diabetes or heart failure. I (A)
-BLOCKERS: • Start and continue indefinitely in all patients who have had myocardial infarction, acute coronary syndrome, or
left ventricular dysfunction with or without heart failure symptoms, unless contraindicated. I (A)
Consider chronic therapy for all other patients with coronary or other vascular disease or diabetes unless
contraindicated. IIa (C)
INFLUENZA VACCINATION: Patients with cardiovascular disease should have an influenza vaccination. I (B)
*Patients covered by these guidelines include those with established coronary and other atherosclerotic vascular disease, including peripheral arterial disease,
atherosclerotic aortic disease, and carotid artery disease. Treatment of patients whose only manifestation of cardiovascular risk is diabetes will be the topic of a
separate AHA scientific statement. ACE indicates angiotensin-converting enzyme.
†Non-HDL-Ctotal cholesterol minus HDL-C.
‡Pregnant and lactating women should limit their intake of fish to minimize exposure to methylmercury.
§When LDL-lowering medications are used, obtain at least a 30% to 40% reduction in LDL-C levels. If LDL-C70 mg/dL is the chosen target, consider drug titration
to achieve this level to minimize side effects and cost. When LDL-C 70 mg/dL is not achievable because of high baseline LDL-C levels, it generally is possible to
achieve reductions of 50% in LDL-C levels by either statins or LDL-C–lowering drug combinations.
Standard dose of statin with ezetimibe, bile acid sequestrant, or niacin.
¶The combination of high-dose statinfibrate can increase risk for severe myopathy. Statin doses should be kept relatively low with this combination. Dietary
supplement niacin must not be used as a substitute for prescription niacin.
#Patients with very high triglycerides should not consume alcohol. The use of bile acid sequestrant is relatively contraindicated when triglycerides are200 mg/dL.
**Creatinine should be 2.5 mg/dL in men and 2.0 mg/dL in women.
††Potassium should be 5.0 mEq/L.
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risk factors and a 10-year risk level for CHD 20%. In the
latter 2 types of high-risk patients, the recommended LDL-C
goal of 100 mg/dL has not changed. Finally, to avoid any
misunderstanding about cholesterol management in general,
it must be emphasized that a reasonable cholesterol level of
70 mg/dL does not apply to other types of lower-risk
individuals who do not have CHD or other forms of athero-
sclerotic disease; in such cases, recommendations contained
in the 2004 ATP III update still pertain.
Trials involving other secondary prevention therapies also
have influenced major practice guidelines used to formulate
the recommendations in this update. Thus, specific recom-
mendations for clopidogrel use in post–acute coronary syn-
drome or post–percutaneous coronary intervention–stented
patients are now included in this 2006 update. The present
update also recommends lower-dose aspirin for chronic
therapy. The results of additional studies have further con-
firmed the benefit of aldosterone antagonist therapy among
patients with impaired left ventricular function. Finally,
recently published findings of a trial involving angiotensin-
converting enzyme inhibitor therapy among patients at rela-
tively low risk with stable coronary disease and normal left
ventricular function influenced the recommendations (26).
The writing group has for the first time added a recom-
mendation with regard to influenza vaccination. According to
the US Centers for Disease Control and Prevention, vaccina-
tion with inactivated influenza vaccine is recommended for
individuals who have chronic disorders of the cardiovascular
system because they are at increased risk for complications
from influenza (38).
The writing group emphasizes the importance of giving
consideration to the use of cardiovascular medications that
have been proved in randomized clinical trials to be of
benefit. This strengthens the evidence-based foundation for
therapeutic application of these guidelines. The committee
acknowledges that ethnic minorities, women, and the elderly
are underrepresented in many trials and urges physician and
patient participation in trials that will provide additional
evidence with regard to therapeutic strategies for these groups
of patients.
In the 11 years since the guidelines were first published, 2
other developments have made them even more important in
clinical care. First, the aging of the population continues to
expand the number of patients living with a diagnosis of
cardiovascular disease (now estimated at 13 million for
coronary heart disease alone) who might benefit from these
therapies. Second, multiple studies of the use of these
recommended therapies in appropriate patients, although
showing slow improvement, continue to support the discour-
aging conclusion that many patients in whom therapies are
indicated are not receiving them in actual clinical practice.
The AHA and ACC recommend the use of programs such as
the AHA’s Get With The Guidelines (39) or the ACC’s
Guidelines Applied to Practice (40) to identify appropriate
patients for therapy, provide practitioners with useful remind-
ers based on the guidelines, and continuously assess the
success achieved in providing these therapies to the patients
who can benefit from them.
TABLE 2. Classification of Recommendations and Level
of Evidence*
Classification of Recommendations
Class I: Conditions for which there is evidence and/or general agreement
that a given procedure or treatment is beneficial, useful, and
effective.
Class II: Conditions for which there is conflicting evidence and/or a
divergence of opinion about the usefulness/efficacy of a
procedure or treatment.
Class IIa: Weight of evidence/opinion is in favor of usefulness/efficacy.
Class IIb: Usefulness/efficacy is less well established by
evidence/opinion.
Class III: Conditions for which there is evidence and/or general
agreement that a procedure/treatment is not useful/effective and
in some cases may be harmful.
Level of Evidence
Level of Evidence A: Data derived from multiple randomized clinical trials
or meta-analyses.
Level of Evidence B: Data derived from a single randomized trial or
nonrandomized studies.
Level of Evidence C: Only consensus opinion of experts, case studies, or
standard-of-care.
*Classification of Recommendations and Level of Evidence are expressed in
the ACC/AHA format and described in more detail in Table 3.
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Appendix
Appendix: References and Supplemental Search Criteria Used to Support Each Recommendation and Level of Evidence
Recommendation References and Supplemental Search Criteria
SMOKING: Primary reference(s) used: 2, 3, 21, 22
Supplemental search done? No
BLOOD PRESSURE: Primary reference(s) used: 2, 4
Supplemental search done? Yes
Database(s) used: PubMed and EMBASE for all English-language human studies
Key words:
PubMed: blood pressure OR hypertension AND practice guidelines and/or prevention and/or clinical trial and/or
pharmacology
EMBASE: secondary prevention OR guidelines AND blood pressure AND Cochrane review OR controlled clinical
trial OR randomized controlled trial AND pharmacology OR hypertension AND Cochrane review OR controlled
clinical trial OR randomized controlled trial AND pharmacology
Years searched: 2003–March 2005
Supplemental search did not alter recommendations.
LIPID MANAGEMENT: Primary reference(s) used: 2, 5, 7
Supplemental search done? Yes
Database used: PubMed for all English-language human studies
Key words: cholesterol/lipids/lipoproteins AND clinical trials and/or meta-analysis and/or practice guidelines
Years searched: 2002–November 2005
Supplemental search added references 6, 8–12, and 33–37 and altered the recommendations.
PHYSICAL ACTIVITY: Primary reference(s) used: 2, 13–16, 21, 22
Supplemental search done? No
WEIGHT MANAGEMENT: Primary reference(s) used: 2, 17–19, 21, 22
Supplemental search done? No
DIABETES MANAGEMENT: Primary reference(s) used: 2, 20–22
Supplemental search done? No
ANTIPLATELET AGENTS/
ANTICOAGULANTS:
Primary reference(s) used: 2, 21–25, 27, 29
Supplemental search done? Yes, for use of ASA after CABG
Database(s) used: PubMed for all English-language studies
Key words: antiplatelet agents, coronary artery bypass graft patency
Years searched: 2000–March 2005
Supplemental search did not alter the recommendations.
RENIN-ANGIOTENSIN-ALDOSTERONE
SYSTEM BLOCKERS:
Primary reference(s) used: 2, 21, 22, 27, 28
Supplemental search done? Yes
Database used: PubMed for all English-language studies
Key words: ACE inhibitor or angiotensin receptor antagonist or aldosterone antagonist AND clinical trials and/or
meta-analysis and/or practice guidelines
Years searched: 2003–March 2005
Supplemental search added references 25 and 30–32 and altered the recommendations.
-BLOCKERS: Primary reference(s) used: 2, 21, 22, 27, 28
Supplemental search done? Yes
Database used: PubMed for all English-language studies
Key words: beta blockers AND clinical trials and/or meta-analysis and/or practice guidelines
Years searched: 2002–March 2005
Supplemental search did not alter recommendations.
INFLUENZA VACCINATION: Primary reference(s) used: 38
Supplemental search done? No
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